BPC-157: what the research shows.
BPC-157 is a 15-amino-acid synthetic peptide derived from a protein found in human gastric juice. It is one of the most-studied healing peptides in rodents — with animal data on tendon, ligament, gut, and wound repair — but it has essentially no published human clinical trials, and it is not approved for human use anywhere.
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid sequence derived from a protein discovered in human gastric juice. Much of the primary research comes from Croatian laboratories, where it was studied extensively from the 1990s onward as PL 14736.
It is not approved for human use by any regulator, and it has no completed human clinical trials published in peer-reviewed literature.
How it works (in animal models)
Across rodent studies, BPC-157 appears to act on several pathways at once:
- Angiogenesis — growth of new small blood vessels around injured tissue, likely via VEGF and related signaling.
- Fibroblast activity — migration and proliferation of the cells that rebuild connective tissue.
- Nitric oxide system — modulation of NO signaling, which may explain effects on both healing and gut protection.
- Gut-brain axis — protective effects on the digestive tract are among its most repeated animal findings.
What researchers are studying
- Tendon-to-bone and muscle-tendon healing
- Skin wound closure and burn repair
- Inflammatory bowel conditions in rodent models
- Protection against NSAID-induced digestive injury
- Nerve regeneration and spinal injury models
For a review of the human-evidence question, see our article does BPC-157 actually have human studies?
What the research shows — and what it doesn't
The animal literature is broad and striking: faster wound closure, improved tendon healing, and gut protection appear repeatedly across multiple labs and models.
The human evidence is essentially absent. There are no published randomized controlled trials in humans, no established safety profile at any dose, and no pharmacokinetic data in people. Unusual pharmacology — oral activity in rodents, which is atypical for peptides — also remains unexplained in humans.
Research limitations
- Nearly all data is rodent or cell research at experimental doses.
- No human safety, dosing, or pharmacokinetic data exists.
- Much of the literature comes from a related cluster of research groups; independent replication is thinner than it appears.
- Stability in solution and identity of what is sold as "BPC-157" varies — see identity testing and how to read a COA.
Common terminology
- Pentadecapeptide — a peptide of 15 amino acids.
- Angiogenesis — formation of new blood vessels.
- Fibroblast — the cell type that builds connective tissue.
- Gastric juice protein — the source material BPC-157's sequence was derived from.
Questions. answered.
Does BPC-157 have human studies?
No published randomized human trials exist. The evidence base is almost entirely rodent and cell studies, and the compound is not approved for human use.
What is BPC-157 made from?
It is a synthetic 15-amino-acid peptide whose sequence comes from a protein naturally present in human gastric juice.
Is BPC-157 legal?
It is not an approved medicine or supplement in the US or EU. It is typically sold as a research chemical, which means it is not evaluated for safety or purity by any regulator.